SMYD2 and pancreatic adenocarcinoma: Tumors and normal tissues of 11 cancer types, such as “breast invasive carcinoma (BRCA), bladder urothelial carcinoma (BLCA), colon adenocarcinoma (COAD), cervical squamous cell carcinoma, endocervical adenocarcinoma (CESC), lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), head and neck squamous cell carcinoma (HNSC), esophageal carcinoma (ESCA), kidney renal clear cell carcinoma (KIRC),”liver hepatocellular carcinoma (LIHC), pancreatic adenocarcinoma (PAAD), and ovarian serous cystadenocarcinoma (OV), were considered for the evaluation of SMYD2 expression differences.